Search

Your search keyword '"Ormiston, John A."' showing total 865 results

Search Constraints

Start Over You searched for: Author "Ormiston, John A." Remove constraint Author: "Ormiston, John A."
865 results on '"Ormiston, John A."'

Search Results

105. Impact trial: Angiographic and intravascular ultrasound observations of the first human experience with mycophenolic acid-eluting polymer stent system

106. Actinomycin-eluting stent for coronary revascularization: A randomized feasibility and safety study: The ACTION trial

108. The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial

110. Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions

112. Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER)

113. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)

114. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies)

116. Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)

118. Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials

120. Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club

121. Long-Term Outcome of Patients from the Auckland Region with Spontaneous Coronary Artery Dissection

123. Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation

124. A new method to quantify boundary conditions using dynamically scaled in vitro MRI for coronary arteries

125. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis : 5-Year Follow-Up

126. Scaled-Up Coronary Flow Measurement using Phase-Contrast MRI

127. Stented Coronary Artery Haemodynamics from Computational Fluid Dynamics (CFD) - CSANZ Poster

130. Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents

131. Change in lumen eccentricity and asymmetry after treatment with Absorb bioresorbable vascular scaffolds in the ABSORB cohort B trial: a five-year serial optical coherence tomography imaging study

132. TCT-17 Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 3-Year Clinical and Imaging Results

134. DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial

135. TCT-32 Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 4-Year Clinical and Imaging Results

137. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy

140. A computational atlas of normal coronary artery anatomy

141. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device:the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)

142. A computational atlas of normal coronary artery anatomy

143. Overcoming spatio-temporal limitations using dynamically scaled in vitro PC-MRI — A flow field comparison to true-scale computer simulations of idealized, stented and patient-specific left main bifurcations

147. RELATION BETWEEN BIORESORBABLE SCAFFOLD SIZING USING QCA-DMAX AND CLINICAL OUTCOMES AT 2 YEARS IN 1192 PATIENTS FROM THREE STUDY COHORTS (ABSORB COHORT B, ABSORB EXTEND AND ABSORB II)

149. Efecto del armazón bioabsorbible liberador de everolimus en la aterosclerosis coronaria

150. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis

Catalog

Books, media, physical & digital resources